|
Company:
|
CTI BIOPHARMA CORP (CTIC)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
3/1/2012
|
|
CIK:
|
0000891293
|
|
Address:
|
3101 WESTERN AVENUE
SUITE 600
|
|
City, State, Zip:
|
SEATTLE, Washington 98121
|
|
Telephone:
|
(206) 282-7100
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$3.30
|
Change:
0.18 (5.77%)
|
Trade Time:
03:54 PM EST
|
Market Cap:
$141.84M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company focused on the acquisition, development and
commercialization of novel targeted therapies covering a spectrum of
blood-related cancers that offer a unique benefit to patients and health care
providers. Our goal is to build a profitable company by generating income from
products we develop and commercialize, either alone or with partners. We are
currently concentrating our efforts on treatments that target blood-related
cancers where there is an unmet medical need. In particular, we are primarily
focused on commercializing PIXUVRI in select countries in the European Union, or
the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin
lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients
with myelofibrosis.
PIXUVRI
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical
properties. In May 2012, the European Commission granted conditional marketing
authorization in the E.
|
|
|
|